Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal
Deal Worth Up To $2.37bn
Executive Summary
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
You may also be interested in...
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
Bayer Advances Parkinson’s Cell And Gene Therapies Into First Human Studies
As Biogen makes history in Alzheimer’s, Bayer is aiming for a breakthrough in Parkinson’s, another major target in neuroscience.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.